Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination responses in immunosuppressed patients with rheumatic autoimmune diseases
NL-OMON32031Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2008
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of influenza vaccine, 23-valent pneumococcal polysaccharide vaccine and Recombivax HB in influenza, pneumococcal disease and hepatitis B (HBV) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Humoral response to influenza vaccination, Humoral response to pneumococcal vaccination and 1 more. Started Sep 2008; status: active, not recruiting.
02
Drugs
influenza vaccine23-valent pneumococcal polysaccharide vaccineRecombivax HB
03
Conditions
influenzapneumococcal diseasehepatitis B (HBV)
Beyond the preview
Go deeper on NL-OMON32031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32031.